NDAINJECTIONINJECTABLE
Approved
Jan 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
OMNISCAN (gadodiamide) by GE HealthCare is magnetic resonance contrast activity [moa]. First approved in 1993.
Drug data last refreshed 17h ago
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Paramagnetic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Started May 2009
213 enrolled
Chronic Kidney DiseaseRenal Insufficiency
A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide
Started Sep 2004
407 enrolled
Aorto-iliac StenosisArterial Occlusive Diseases
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Started Sep 2003
395 enrolled
Renal Artery Stenosis
A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
Started Jul 2003
Worked on OMNISCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.